Clinical DataPreclinical data demonstrated that PBGENE-HBV eliminated approximately 85% of covalently closed circular DNA (cccDNA) in human primary hepatocytes and inactivated the majority of integrated DNA (intDNA), which supports the potential to achieve clinical endpoints.
Regulatory ProgressFast Track designation from the FDA for ECUR-506, an in vivo gene insertion therapy designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency.
Technological MilestonesPrecision is on track to hit multiple milestones to validate their ARCUS genome editing technology.